CytomX Therapeutics (CTMX) Competitors $2.46 -0.03 (-1.01%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. NUVB, TRVI, ANAB, PHAT, URGN, IMTX, DAWN, ABUS, STOK, and SIONShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), AnaptysBio (ANAB), Phathom Pharmaceuticals (PHAT), Urogen Pharma (URGN), Immatics (IMTX), Day One Biopharmaceuticals (DAWN), Arbutus Biopharma (ABUS), Stoke Therapeutics (STOK), and Sionna Therapeutics (SION). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Nuvation Bio Trevi Therapeutics AnaptysBio Phathom Pharmaceuticals Urogen Pharma Immatics Day One Biopharmaceuticals Arbutus Biopharma Stoke Therapeutics Sionna Therapeutics Nuvation Bio (NYSE:NUVB) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation. Does the media favor NUVB or CTMX? In the previous week, Nuvation Bio and Nuvation Bio both had 3 articles in the media. CytomX Therapeutics' average media sentiment score of 1.24 beat Nuvation Bio's score of 0.65 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals have more ownership in NUVB or CTMX? 61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer NUVB or CTMX? Nuvation Bio currently has a consensus price target of $7.17, indicating a potential upside of 245.05%. CytomX Therapeutics has a consensus price target of $5.33, indicating a potential upside of 117.24%. Given Nuvation Bio's stronger consensus rating and higher possible upside, research analysts clearly believe Nuvation Bio is more favorable than CytomX Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuvation Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NUVB or CTMX more profitable? CytomX Therapeutics has a net margin of 28.22% compared to Nuvation Bio's net margin of -5,534.21%. Nuvation Bio's return on equity of -44.14% beat CytomX Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nuvation Bio-5,534.21% -44.14% -32.97% CytomX Therapeutics 28.22%-553.71%32.21% Which has more risk and volatility, NUVB or CTMX? Nuvation Bio has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500. Which has higher valuation & earnings, NUVB or CTMX? CytomX Therapeutics has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNuvation Bio$7.87M89.80-$567.94M-$2.35-0.88CytomX Therapeutics$138.10M1.43$31.87M$0.485.11 SummaryCytomX Therapeutics beats Nuvation Bio on 9 of the 16 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$197.92M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E Ratio5.1121.2326.5720.02Price / Sales1.43280.33415.46120.95Price / Cash6.5241.4736.1356.90Price / Book-245.507.498.065.50Net Income$31.87M-$55.05M$3.15B$248.50M7 Day Performance6.28%2.58%1.72%2.61%1 Month Performance-7.36%5.22%3.92%5.42%1 Year Performance88.85%5.04%35.02%20.76% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.3942 of 5 stars$2.46-1.0%$5.33+117.2%+87.9%$197.92M$138.10M5.11170News CoveragePositive NewsNUVBNuvation Bio3.4957 of 5 stars$2.02+2.3%$7.17+255.7%-31.0%$685.62M$7.87M-0.8660High Trading VolumeTRVITrevi Therapeutics3.1123 of 5 stars$5.75-3.5%$20.29+252.8%+123.1%$674.42MN/A-12.7820News CoverageAnalyst ForecastAnalyst RevisionANABAnaptysBio2.1262 of 5 stars$22.82-1.5%$42.38+85.7%-0.3%$670.45M$91.28M-4.71100Positive NewsPHATPhathom Pharmaceuticals4.067 of 5 stars$9.47-9.1%$17.50+84.8%-13.1%$661.14M$81.86M-1.81110Positive NewsHigh Trading VolumeURGNUrogen Pharma4.5612 of 5 stars$14.30-2.4%$32.86+129.8%-14.4%$659.37M$90.40M-4.50200High Trading VolumeIMTXImmatics3.1045 of 5 stars$5.42-3.4%$14.67+170.6%-53.5%$658.80M$168.65M-31.88260DAWNDay One Biopharmaceuticals2.1582 of 5 stars$6.48+2.5%$30.57+371.8%-50.0%$656.81M$131.16M-9.1360Upcoming EarningsABUSArbutus Biopharma1.9509 of 5 stars$3.41-0.6%$5.50+61.3%+1.9%$653.12M$6.17M-8.3290STOKStoke Therapeutics4.0302 of 5 stars$11.59+0.1%$23.20+100.2%-10.0%$632.78M$190.91M14.67100Analyst ForecastSIONSionna TherapeuticsN/A$14.10-2.7%$38.50+173.0%N/A$622.15MN/A0.0035News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies Nuvation Bio Competitors Trevi Therapeutics Competitors AnaptysBio Competitors Phathom Pharmaceuticals Competitors Urogen Pharma Competitors Immatics Competitors Day One Biopharmaceuticals Competitors Arbutus Biopharma Competitors Stoke Therapeutics Competitors Sionna Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
